Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HOLX 
Hologic Inc (HOLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: HOLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $67.27
1 Year Target Price $67.27
| 3 | Strong Buy |
| 3 | Buy |
| 14 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.03% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.44B USD | Price to earnings Ratio 27.22 | 1Y Target Price 67.27 |
Price to earnings Ratio 27.22 | 1Y Target Price 67.27 | ||
Volume (30-day avg) 20 | Beta 0.55 | 52 Weeks Range 51.90 - 84.67 | Updated Date 07/3/2025 |
52 Weeks Range 51.90 - 84.67 | Updated Date 07/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.83% | Operating Margin (TTM) 22.17% |
Management Effectiveness
Return on Assets (TTM) 6.92% | Return on Equity (TTM) 11.77% |
Valuation
Trailing PE 27.22 | Forward PE 14.45 | Enterprise Value 15459566111 | Price to Sales(TTM) 3.59 |
Enterprise Value 15459566111 | Price to Sales(TTM) 3.59 | ||
Enterprise Value to Revenue 3.84 | Enterprise Value to EBITDA 14.03 | Shares Outstanding 222844992 | Shares Floating 220734902 |
Shares Outstanding 222844992 | Shares Floating 220734902 | ||
Percent Insiders 0.86 | Percent Institutions 102.61 |
Upturn AI SWOT
Hologic Inc
Company Overview
History and Background
Hologic Inc. was founded in 1985. It initially focused on bone densitometry and has since expanded into women's health, diagnostics, and surgical products. Significant milestones include the development of the first FDA-approved bone densitometer, expansion into breast health with acquisitions, and growth in molecular diagnostics.
Core Business Areas
- Diagnostics: Develops and manufactures diagnostic tests for infectious diseases, including women's health, respiratory health, and virology.
- Breast Health: Offers a comprehensive suite of breast imaging and interventional solutions, including mammography, tomosynthesis, and biopsy devices.
- Gynecological Surgical Solutions: Provides minimally invasive surgical products for gynecological procedures, including hysteroscopy and endometrial ablation.
- Skeletal Health: Produces bone densitometry systems for assessing bone health and diagnosing osteoporosis.
Leadership and Structure
Stephen P. MacMillan is the Chairman, President, and CEO. The company has a board of directors and operates with a functional organizational structure, dividing responsibilities across its core business areas.
Top Products and Market Share
Key Offerings
- Gen-Probe Panther System: A fully automated, integrated platform for molecular diagnostics, enabling high-throughput testing for infectious diseases. Competitors include Roche (RHHBY), Abbott (ABT), and Siemens Healthineers (SIEGY). Revenue estimated at $1.5 Billion 2023.
- Selenia Dimensions Mammography System: A 3D mammography system for breast cancer screening and diagnosis. Hologic is a leading provider in this market. Competitors include GE Healthcare (GE), Siemens Healthineers (SIEGY), and Fujifilm (FUJIY).
- MyoSure System: A hysteroscopic tissue removal system for the treatment of abnormal uterine bleeding. Competitors include Medtronic (MDT) and Boston Scientific (BSX).
- Aptima Assays: Hologicu2019s Aptima family of assays provides molecular diagnostic solutions for women's health, infectious diseases, and virology. Competitors include Roche, Abbott, and Siemens.
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in diagnostics and treatment. Personalized medicine and minimally invasive procedures are growing areas.
Positioning
Hologic is a leading player in the women's health market, with strong positions in breast health, diagnostics, and surgical solutions. Its competitive advantages include a strong brand reputation, innovative products, and a broad portfolio of solutions. High switching costs are also a competitive advantage
Total Addressable Market (TAM)
The global women's health market is expected to reach $51.4 billion by 2028. Hologic is well-positioned to capture a significant share of this market through its diverse product portfolio and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Leading market position in women's health
- Strong brand reputation
- Innovative product portfolio
- Extensive distribution network
- High switching costs
Weaknesses
- Dependence on specific product lines
- Exposure to regulatory changes
- Potential for product liability claims
- Reliance on third-party suppliers
Opportunities
- Expanding into new markets
- Developing new products and technologies
- Acquiring complementary businesses
- Increasing adoption of preventative care
- Growing demand for personalized medicine
Threats
- Increasing competition
- Pricing pressures
- Technological obsolescence
- Changes in reimbursement policies
- Economic downturns
Competitors and Market Share
Key Competitors
- Roche Holding AG (RHHBY)
- Abbott Laboratories (ABT)
- Siemens Healthineers (SIEGY)
- GE HealthCare Technologies Inc. (GEHC)
Competitive Landscape
Hologic benefits from its specialization in women's health, while Roche, Abbott, and Siemens have broader healthcare portfolios. Hologic's focus allows for greater innovation and market penetration within its niche.
Major Acquisitions
Biotheranostics
- Year: 2021
- Acquisition Price (USD millions): 230
- Strategic Rationale: Enhanced Hologic's oncology testing business with Biotheranostics' molecular diagnostic tests for breast and other cancers.
Cynosure
- Year: 2017
- Acquisition Price (USD millions): 1650
- Strategic Rationale: Expanded Hologic's portfolio into the medical aesthetics market, adding energy-based aesthetic treatment systems.
Growth Trajectory and Initiatives
Historical Growth: Hologic has experienced strong revenue growth over the past decade, driven by organic growth and strategic acquisitions.
Future Projections: Analysts project continued revenue growth for Hologic, driven by demand for its products and services. Earnings are expected to grow in line with revenue.
Recent Initiatives: Recent strategic initiatives include acquisitions to expand its product portfolio, investments in research and development, and expansion into new geographic markets.
Summary
Hologic is a strong company with a leading position in the women's health market. Its focus on innovation and strategic acquisitions has driven growth. However, it should be mindful of increasing competition, pricing pressures, and technological obsolescence to maintain its competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hologic Inc. SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hologic Inc
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1990-06-21 | Chairman, CEO & President Mr. Stephen P. MacMillan | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 7063 | Website https://www.hologic.com |
Full time employees 7063 | Website https://www.hologic.com | ||
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.